Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial

Anticancer Res. Mar-Apr 1997;17(2B):1223-6.

Abstract

76 colon adenocarcinoma patients (stages 1-3, NO, MO) were enrolled into a prospectively randomized clinical trial, 39 patients were perioperatively treated with D-galactose-(therapy group: 1.9 g/kg BW and day) or D-glucose-containing electrolyte infusions (control group: n = 37). There were no cases of perioperative mortality. The complication rate was 17.1% (therapy group: 15.3%; control group: 18.9%). Since tumor staging and grading were equally distributed for therapy and control groups, a non-stratified statistical analysis yielded a) significantly reduced hepatic metastases and b) improved overall survival for patients of the therapy group. Stage-dependent analysis demonstrated that stage 3 carcinoma patients of the treatment group developed significantly less hepatic metastases as compared to patients of the control group.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Colonic Neoplasms / drug therapy*
  • Female
  • Galactose / therapeutic use*
  • Humans
  • Lectins / antagonists & inhibitors*
  • Liver Neoplasms / prevention & control*
  • Liver Neoplasms / secondary*
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Lectins
  • Galactose